PDF herunterladen
CC BY-NC-ND 4.0 · Endosc Int Open 2019; 07(12): E1763-E1767
DOI: 10.1055/a-0982-3194
Original article
Owner and Copyright © Georg Thieme Verlag KG 2019

Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding

Jin-Seok Park
Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
,
Hyung Kil Kim
Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
,
Yong Woon Shin
Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
,
Kye Sook Kwon
Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
,
Don Haeng Lee
Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 16. Mai 2019

accepted after revision 05. Juli 2019

Publikationsdatum:
10. Dezember 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gastrointestinal bleeding (NVUGIB).

Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed by reviewing patient medical records.

Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully applied at bleeding site in all cases. The success rate of immediate hemostasis was 96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred.

Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when used as monotherapy and showed promising results in terms of preventing rebleeding.

 

  • References

  • 1 Hearnshaw SA, Logan RF, Lowe D. et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335
    CrossrefPubMedSuche in Google Scholar
  • 2 Barkun AN, Bardou M, Kuipers EJ. et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152: 101-113
    PubMedSuche in Google Scholar
  • 3 Yau AHL, Ou G, Galorport C. et al. Safety and efficacy of Hemospray® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol 2014; 28: 72-76
    PubMedSuche in Google Scholar
  • 4 Smith LA, Stanley AJ, Bergman JJ. et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-e92
    CrossrefPubMedSuche in Google Scholar
  • 5 Chen Y, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015; 47: 167-171
    Thieme ConnectPubMedSuche in Google Scholar
  • 6 Sulz MC, Frei R, Meyenberger C. et al. Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland. Endoscopy 2014; 46: 619-624
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Cahyadi O, Bauder M, Meier B. et al. Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience. Endosc Int Open 2017; 5: E1159
    Thieme ConnectPubMedSuche in Google Scholar
  • 8 Haddara S, Jacques J, Lecleire S. et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 2016; 48: 1084-1095
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Park J, Bang BW, Hong SJ. et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy 2019; 5: 458-462
    Thieme ConnectPubMedSuche in Google Scholar
  • 10 Huang R, Pan Y, Hui N. et al. Polysaccharide hemostatic system for hemostasis management in colorectal endoscopic mucosal resection. Dig Endosc 2014; 26: 63-68
    CrossrefPubMedSuche in Google Scholar
  • 11 Kurt M, Akdogan M, Onal IK. et al. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis. Dig Liver Dis 2010; 42: 196-199
    CrossrefPubMedSuche in Google Scholar
  • 12 Sung J, Luo D, Wu J. et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Smith LA, Stanley AJ, Bergman JJ. et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-e92
    CrossrefPubMedSuche in Google Scholar
  • 14 Aslanian HR, Laine L. Hemostatic powder spray for GI bleeding. Gastrointest Endosc 2013; 77: 508-510
    CrossrefPubMedSuche in Google Scholar
  • 15 Sung J, Luo D, Wu J. et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Barkun A. New topical hemostatic powders in endoscopy. Gastroenterol Hepatol (NY) 2013; 9: 744-746
    PubMedSuche in Google Scholar